Journal
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
Volume 16, Issue 4, Pages 304-307Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MED.0b013e32832d88e4
Keywords
acromegaly; growth hormone receptor antagonist; lanreotide; octreotide; pegvisomant; radiosurgery; somatostatin receptor analogs; transphenoidal surgery
Categories
Ask authors/readers for more resources
Purpose of review Description of recent outcomes and approaches to the treatment of patients with de-novo and recurrent acromegaly. Recent findings Radiosurgery for acromegaly results in a higher likelihood of remission and an earlier time to remission than does conventional radiotherapy. Somatostatin analogs results in control of acromegaly and one half of patients. Combining treatment with pegvisomant and somatostatin analogs results in overall improved quality of life. Summary Existing treatments offer patients and their treating physicians opportunities to restore life expectancy to normal and reverse many of the symptoms and signs of acromegaly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available